Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
100 hedge funds and large institutions have $714M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 51 increasing their positions, 18 reducing their positions, and 14 closing their positions.
638% more call options, than puts
Call options by funds: $72.7M | Put options by funds: $9.85M
183% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 18
71% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 14
37% more capital invested
Capital invested by funds: $523M → $714M (+$191M)
11% more funds holding
Funds holding: 90 → 100 (+10)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$79.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$72.2M |
| 3 |
BlackRock
New York
|
+$22M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$19.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$48.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.8M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.1M |
| 5 |
VMI
VHCP Management II
New York
|
-$9.81M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
American Century Companies
Kansas City,
Missouri
| – | -$1.54M | -57,216 | Closed |
|
102
Norges Bank
Oslo,
Norway
| – | -$1.35M | -50,000 | Closed |
|
103
Invesco
Atlanta,
Georgia
| – | -$748K | -27,723 | Closed |
|
|
PAM
104
Panagora Asset Management
Boston,
Massachusetts
| – | -$662K | -24,548 | Closed |
|
|
SO
105
STRS Ohio
Columbus,
Ohio
| – | -$491K | -18,200 | Closed |
|
|
TI
106
Trexquant Investment
Stamford,
Connecticut
| – | -$346K | -12,836 | Closed |
|
|
CSS
107
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$337K | -12,492 | Closed |
|
|
ECM
108
Endurant Capital Management
San Mateo,
California
| – | -$278K | -10,300 | Closed |
|
|
MC
109
Matisse Capital
Portland,
Oregon
| – | -$270K | -10,000 | Closed |
|
|
PHK
110
Point72 Hong Kong
Hong Kong
| – | -$32K | -1,187 | Closed |
|
111
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$2K | -91 | Closed |
|
|
RCAG
112
Rehmann Capital Advisory Group
Lansing,
Michigan
| – | +$508 | +17 | New |
|
BHVN Hedge Fund Activity: Q1 2018 in Review
100 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q1 2018, worth a combined $714M — up 37% from $523M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new BHVN positions and 14 closed out — a net gain of 10 holders — while 51 added to existing stakes and 18 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $79.7M. The largest seller was RA Capital Management, cutting an estimated $48.8M.
- 100 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q1 2018, up from 90 in Q4 2017.
- Funds reported $714M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q1 2018, up 37% quarter-over-quarter.
- 24 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q1 2018 and 14 closed out, a net change of +10 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q1 2018 was Perceptive Advisors, an estimated $79.7M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q1 2018 was RA Capital Management, an estimated $48.8M sold.
Based on aggregated 13F filings for Q1 2018.